tiprankstipranks
Top Stocks
U.S. Stock Market OverviewTop Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
Top ETFs by AUMSPY ETFQQQ ETF
Stock Comparison
Energy StocksOil StocksBest Value StocksAirline StocksElectric Vehicle StocksMATANA Stocks
New
Bank StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
Global Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsTools for Trading PlatformsData for Hedge FundsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Top ETFs by AUM
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
U.S. Markets
Market Movers
Expert Center
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
Top ETFs by AUM
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Energy Stocks
EV Stocks
Crypto News
Dividend Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

GSK Stock Latest News

GSK, Cytel enter three-year agreement to expand Solara deployment
The FlyGSK, Cytel enter three-year agreement to expand Solara deployment
1d ago
GSK
GSK price target raised to 1,400 GBp from 1,350 GBp at JPMorgan
The FlyGSK price target raised to 1,400 GBp from 1,350 GBp at JPMorgan
6d ago
GSK
Akebia should update on vadadustat FDA process in next month, says Piper Sandler
The FlyAkebia should update on vadadustat FDA process in next month, says Piper Sandler
6d ago
GSK
AKBA
GSK reports Jesduvroq approved by FDA for anemia of CKD in adults on dialysis
The FlyGSK reports Jesduvroq approved by FDA for anemia of CKD in adults on dialysis
6d ago
GSK
Ionis Pharmaceuticals: GSK advances bepirovirsen into Phase 3 development
The FlyIonis Pharmaceuticals: GSK advances bepirovirsen into Phase 3 development
7d ago
GSK
IONS
GSK sees FY23 adjusted EPS up 12%-15%, adjusted operating profit up 10%-12%
The FlyGSK sees FY23 adjusted EPS up 12%-15%, adjusted operating profit up 10%-12%
7d ago
GSK
GSK reports Benlysta granted orphan drug designation by FDA
The FlyGSK reports Benlysta granted orphan drug designation by FDA
7d ago
GSK
GSK reports Q4 adjusted EPS 25.8p vs. 23.6p last year
The FlyGSK reports Q4 adjusted EPS 25.8p vs. 23.6p last year
7d ago
GSK
JMP Securities says older-adult update continues to look encouraging for CureVac
The FlyJMP Securities says older-adult update continues to look encouraging for CureVac
9d ago
GSK
CVAC
CureVac announces data in older adults from COVID-19, flu mRNA vaccines
The FlyCureVac announces data in older adults from COVID-19, flu mRNA vaccines
9d ago
GSK
CVAC
GSK’s belimumab granted orphan designation as treatment of systemic sclerosis
The FlyGSK’s belimumab granted orphan designation as treatment of systemic sclerosis
15d ago
GSK
Moderna price target raised to $111 from $102 at SVB Securities
The FlyModerna price target raised to $111 from $102 at SVB Securities
21d ago
GSK
JNJ
Regenxbio names Curran Simpson as COO
The FlyRegenxbio names Curran Simpson as COO
30d ago
GSK
RGNX
CureVac upgraded to Buy at Jefferies after mRNA platform validation
The FlyCureVac upgraded to Buy at Jefferies after mRNA platform validation
1M ago
GSK
CVAC
HilleVax announces executive management appointments, promotions
The FlyHilleVax announces executive management appointments, promotions
1M ago
GSK
HLVX
CureVac ‘likely too late for COVID upside,’ says BofA
The FlyCureVac ‘likely too late for COVID upside,’ says BofA
1M ago
GSK
CVAC
CureVac announces data on joint COVID-19, Flu mRNA vaccine programs
The FlyCureVac announces data on joint COVID-19, Flu mRNA vaccine programs
1M ago
GSK
CVAC
Morgan Stanley sees Moderna’s phase 3 RSV vaccine data as catalyst-driven idea
The FlyMorgan Stanley sees Moderna’s phase 3 RSV vaccine data as catalyst-driven idea
1M ago
GSK
PFE
GSK, WuXi Biologics enter into license agreement on TCE antibodies
The FlyGSK, WuXi Biologics enter into license agreement on TCE antibodies
1M ago
GSK
GSK downgraded to Underweight from Neutral at JPMorgan
The FlyGSK downgraded to Underweight from Neutral at JPMorgan
1M ago
GSK
Barclays views GSK acquisition interest as positive for oncology stocks
The FlyBarclays views GSK acquisition interest as positive for oncology stocks
1M ago
GSK
ARVN
GSK seeks under-appreciated biotechs ‘hiding in plain sight’, FT reports
The FlyGSK seeks under-appreciated biotechs ‘hiding in plain sight’, FT reports
1M ago
GSK
Pfizer, Moderna among vaccine makers to watch in 2023, Barron’s says
The FlyPfizer, Moderna among vaccine makers to watch in 2023, Barron’s says
2M ago
GSK
PFE
ProQR Therapeutics price target raised to $5 from $2 at Raymond James
The FlyProQR Therapeutics price target raised to $5 from $2 at Raymond James
2M ago
GSK
LLY
Sanofi, Pfizer settled first California Zantac bellwether case, says Barclays
The FlySanofi, Pfizer settled first California Zantac bellwether case, says Barclays
2M ago
GSK
HLN
Biotech Alert: Searches spiking for these stocks today
The FlyBiotech Alert: Searches spiking for these stocks today
2M ago
GSK
RNA
Biotech Alert: Searches spiking for these stocks today
The FlyBiotech Alert: Searches spiking for these stocks today
2M ago
GSK
LLY
Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential
The FlyVaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential
2M ago
GSK
MRK
Wave Life Sciences Soars on GSK Deal
Market NewsWave Life Sciences Soars on GSK Deal
2M ago
GSK
WVE
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.